Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
OABI dropped 11.6% on October 6 to close at $4.35, a sharp single-day move that arrived the same morning two analysts raised their price targets, creating one of the starker divergences between Street conviction and market action seen in small-cap biotech this week.
The analyst moves are the clearest signal worth examining. Leerink Partners raised its target from $10 to $12, maintaining an Outperform rating. StoneX lifted its target from $4 to $6, also keeping a Buy. Both actions were filed on October 7, the day after the selloff. HC Wainwright held a Buy with an $11 target in August. That puts the consensus mean price target at roughly $8.33, nearly double the current $4.35 print. The bull case centres on OmniAb's antibody discovery platform generating royalty-bearing partnerships, a balance sheet that supports ongoing operations, and anticipated R&D catalysts. Bears point to cash burn, a stock that has traded well below its post-merger highs for much of its life, and revenues still measured in single-digit millions. With targets from $6 to $12 against a $4.35 price, the Street is collectively sitting far above where buyers are willing to transact today.
Short positioning tells a more moderate story, though the trend is worth watching. Short interest has climbed to 5.1% of the free float, up 16% over the past month and reaching its highest level in the period covered by the history. That is meaningful but not extreme. The borrow market is notably loose: availability runs at 828%, meaning roughly eight shares are available to lend for every one already borrowed. Cost to borrow is 0.48%, a low rate that has eased from above 2% in late August, when a brief squeeze appeared and quickly unwound. With borrow so cheap and supply so ample, there is no mechanical pressure on existing short positions. The ORTEX short score of 48.3 sits near the middle of its range, having ticked up from 44.7 two weeks ago but still well short of levels that would signal acute squeeze risk.
Options positioning leans away from hedging rather than toward it. The put/call ratio of 0.08 is actually below its 20-day average of 0.10, about one standard deviation light on the put side. That means options buyers have not rushed to protect against further downside following the selloff, which is an unusual response to a 12% drop. The PCR was last higher, around 0.13, in mid-September. The current reading is near the low end of the 52-week range.
On the ownership register, Whitefort Capital trimmed its stake by roughly 4 million shares as of June 30 but remains the largest institutional holder at about 7% of shares. BlackRock added around 790,000 shares through the end of September. Janus Henderson moved in the other direction, cutting its position from 6.6% to 0.8% as of August, a significant exit. Robert Goldstein holds 8.5% as last disclosed in a February 13G/A filing, though that stake and all 13D/G disclosures reflect positions around the 5% filing threshold; holders who drop below that level may not file again. No 13D activist is on the register.
Next up is a Q3 earnings report scheduled for November 5. The last earnings event, on August 6, produced a one-day move of 52% and a five-day follow-through of 69%, so the print carries outsized historical significance regardless of direction. With the stock now at $4.35 and analysts clustered between $6 and $12, the November 5 report and any partnership or licensing news ahead of it are the key events to track.
See the live data behind this article on ORTEX.
Open OABI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
